Ignite Creation Date:
2024-05-06 @ 6:18 PM
Last Modification Date:
2024-10-26 @ 2:45 PM
Study NCT ID:
NCT05613478
Status:
RECRUITING
Last Update Posted:
2022-11-14
First Post:
2022-11-06
Brief Title:
Camrelizumab Combined With Apatinib Mesylate and TACE in the Perioperative Treatment of Hepatocellular Carcinoma
Sponsor:
The First Affiliated Hospital with Nanjing Medical University
Organization:
The First Affiliated Hospital with Nanjing Medical University
Organization Data
Organization:
The First Affiliated Hospital with Nanjing Medical University
Class:
OTHER
Study ID:
Xuehao Wang
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
The First Affiliated Hospital with Nanjing Medical University
Lead Sponsor Class:
OTHER
Responsible Party:
Xuehao Wang
Responsible Party Title:
professor
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
The First Affiliated Hospital with Nanjing Medical University
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Jiangsu Hengrui Pharmaceutical Co Ltd | INDUSTRY |